PRESS RELEASE published on 10/21/2025 at 18:49, 1 year ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 1 year ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 1 year ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 1 year 1 month ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 1 year 1 month ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
BRIEF published on 08/28/2025 at 18:56, 1 year 2 months ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 1 year 2 months ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
BRIEF published on 08/27/2025 at 19:31, 1 year 2 months ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 08/27/2025 at 19:26, 1 year 2 months ago Inside Information / Other news releases ABIONYX Pharma initiates discussions with a major sepsis player for strategic partnership, aiming to accelerate CER-001 development. Relevance of innovative technology validated Strategic Partnership Innovative Technology ABIONYX Pharma Sepsis CER-001
BRIEF published on 08/21/2025 at 23:20, 1 year 2 months ago ABIONYX: Capital structure and voting rights as of July 31, 2025 Euronext Paris Share Capital Voting Rights Actions ABIONYX
Published on 10/30/2026 at 23:35, 2 days 10 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 10 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 14 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 18 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 09:30, 26 minutes ago Europe's first bond for New Space investing is open for subscription from today: European Space Bond, 8% p.a. fixed interest.
Published on 11/02/2026 at 09:20, 36 minutes ago Original-Research: SFC Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 09:00, 56 minutes ago Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 56 minutes ago Original-Research: bet-at-home.com AG (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 56 minutes ago Mutares has sold SRT Group and its subsidiaries to Quiver
Published on 10/30/2026 at 23:00, 2 days 10 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 15 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 21 hours ago Capital increase through exercise of subscription rights
